This is a retrospective/prospective observational multicentric trial on patients with bone metastases from NENs. General objectives: * To trace on a national scale the frequency of bone metastases in patients with neuroendocrine neoplasm (NEN) and their clinical management. * To correlate clinical and biological factors to clinical outcomes. * To centralise and to make homogeneous clinical, pathological, instrumental and therapeutic information. * To set up a database and to acquire biological material for studying predictive and prognostic biomarkers.
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Overall survival
Timeframe: 01/2021 - 12/2021
Influence of skeletal related events (SRE) on survival
Timeframe: 01/2021 - 12/2021
Correlation between SRE and time from bone metastasis and SRE, site of one metastases, number of bone metastases, morphology of bone metastases, LDH
Timeframe: 01/2021 - 12/2021
Influence of the use of bisphosphonates or RANK-ligands
Timeframe: 01/2021 - 12/2021